LAWRENCE, EVANS & CO., LLC

Investment Banking | Healthcare Finance | Consulting

JP Morgan Healthcare Week Special Edition 2025 News and Deals

1. Novartis (SWX: NOVN) CEO Predicts Kisqali to Become Company's Best-Selling Drug, Dominating Breast Cancer Market

   Novartis CEO Vas Narasimhan has expressed strong confidence that the breast cancer drug Kisqali (ribociclib) will become the company's highest-selling drug ever. Speaking at the JP Morgan Healthcare Conference, Narasimhan highlighted Kisqali's remarkable turnaround since its 2017 launch. The drug has gained significant market share in metastatic HR-positive, HER2-negative breast cancer, outperforming competitors like Pfizer's Ibrance. Kisqali's recent approval for early-stage high-risk patients has further boosted its prospects, with a 52% share of new prescriptions in the US market just months after launch. This success in both advanced and early-stage treatments has dramatically improved Kisqali's long-term revenue projections. (Link)

2. Vaccine CEOs Paul Hudson (Sanofi) and Emma Walmsley (GSK) Embrace Transparency Amid Anti-Vaccine Challenges

   The anti-vaccine movement in the U.S., spurred by President-elect Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services, has raised concerns for vaccine makers like Sanofi and GSK. At the J.P. Morgan Healthcare Conference, CEOs Paul Hudson (Sanofi) and Emma Walmsley (GSK) welcomed transparent discussions on vaccine performance. Hudson emphasized the importance of addressing misinformation with facts, while Walmsley highlighted the critical role vaccines play in preventing disease and reducing hospitalizations. Both leaders reaffirmed their commitment to transparency and trust, stressing the significance of the U.S. market for their businesses, with GSK alone employing 15,000 people in the country and making significant investments. (Link)

3. Regeneron (NAS: REGN) Faces Sales Setback for Eylea HD Amid Optimism for Pipeline Expansion

   At the J.P. Morgan Healthcare Conference, Regeneron's leadership balanced enthusiasm for their promising drug pipeline with concerns over Eylea HD's lacklustre sales. While CEO Len Schleifer expressed a preference to highlight innovation, he addressed the $305 million U.S. revenue for Eylea HD in Q4 2024—a steep decline from the previous quarter's $392 million and far below analyst expectations of $411 million. Approved in August 2023, Eylea HD initially showed growth, but Schleifer acknowledged the need for enhancements, including FDA approvals for a prefilled syringe option and an extended dosing interval for macular degeneration by mid-2025.(Link)

4. Teladoc Health (NYSE: TDOC) Eyes Growth Amid Financial Challenges, Partners with Amazon (NAS: AMZN) for Chronic Care Expansion

   Teladoc Health, with 93 million members and 10,000 customers, faces pressure in the competitive telehealth market. Despite a 1% revenue decline to $1.9 billion in 2024 and a significant net loss of $953 million, the company sees growth potential through its extensive network of health plans, systems, employers, and consumers. CEO Chuck Divita, who joined in June, aims to improve performance and recovery from declining stock prices. Teladoc's comprehensive virtual care

services, including primary care, urgent care, mental health, and chronic condition management, continue to operate at a significant scale. (Link)

5. CommonSpirit Health Launches "One CommonSpirit" Initiative, Aims for Unified Operations and Improved Financial Performance

   CommonSpirit Health, a $37 billion nonprofit health system, unveiled its "One CommonSpirit" initiative at the 2024 J.P. Morgan Healthcare Conference. CEO Wright Lassiter III reported significant progress in unifying programs, platforms, and strategic goals across the organization. The initiative aims to streamline operations, including consolidating electronic health record systems and implementing national programs. CommonSpirit has seen improvements in quality metrics, patient satisfaction, and financial performance. The health system is also focusing on portfolio realignment, launching partnerships, and expanding ambulatory services to ensure financial sustainability. Despite facing challenges, CommonSpirit is committed to adapting to market needs while maintaining a unified approach. (Link)

6. Health Catalyst (NAS:HCAT) to Acquire Upfront Healthcare Services, Boosting Patient Engagement Capabilities

   Health Catalyst (HCAT) has announced a definitive agreement to acquire Upfront Healthcare Services, a patient engagement platform provider. The acquisition, set to close in Q1 2025, aims to enhance Health Catalyst's offerings in patient engagement and care transitions. By integrating Upfront's technology, Health Catalyst plans to improve its clinical improvement and ambulatory operations focus, ultimately helping healthcare clients provide better patient care. Health Catalyst, a leading provider of data and analytics technology for healthcare organizations, supports over 1,000 organizations worldwide. The company's YTD price performance is -6.07%, with a current market cap of $419.2M. (Link)

7. NVIDIA (NAS:NVDA) and Mayo Clinic Forge Groundbreaking Partnership to Revolutionize Digital Pathology and Advance AI in Healthcare

   NVIDIA and Mayo Clinic announced a transformative collaboration at the 2025 J.P. Morgan Healthcare Conference, aimed at accelerating next-generation digital pathology. The partnership will leverage NVIDIA's latest AI platforms, including the DGX B200 and MONAI, to enhance Mayo Clinic's digital pathology infrastructure. The collaboration extends to developing human digital twins for personalized medicine and advancing physical AI in healthcare. Mayo Clinic's vast database of 10 million patient records and 20 million high-resolution slide images will be utilized to create foundational AI models. This partnership is part of NVIDIA's broader investment in healthcare, with additional collaborations announced with IQVIA, Illumina, and Arc Institute. (Link)

8. Intermountain Health to Build $1 Billion Children's Hospital in Las Vegas, Addressing Critical Healthcare Gap

   Intermountain Health has announced plans to construct Las Vegas's first stand-alone pediatric hospital at UNLV's Harry Reid Research and Technology Park. The facility aims to address a significant healthcare gap in the largest U.S. metro area without a dedicated children's hospital. Expected to serve approximately 500,000 children in the area, the hospital will offer comprehensive pediatric services, including 10,000 annual admissions and 24,000 emergency visits. This move expands Intermountain's presence in Southern Nevada, where it already operates 65 clinics. The project, estimated to cost around $1 billion, will allow local children to receive critical care without traveling to surrounding states. (Link)

9. Waystar (NAS:WAY) Unveils AI-Powered Tool to Tackle Healthcare Claim Denials, Boosting Revenue Recovery

Waystar, a healthcare payment software company, has launched Waystar AltitudeAI, a comprehensive AI solution for providers. The centerpiece is a generative AI tool that autonomously generates appeal letters for denied claims. Announced at the J.P. Morgan Healthcare Conference, this innovation aims to help providers recover payments from the 450 million annually denied claims. Waystar, which went public in June raising $967.5 million, serves over 30,000 customers and processes more than $1.2 trillion in annual gross claims. The company's CEO, Matt Hawkins, emphasized the tool's potential to transform healthcare payment workflows and address the growing issue of claim denials. (Link)

10. Coalition for Health AI (CHAI) Launches AI Prior Authorization Working Group

CHAI, a nonprofit focused on responsible AI in healthcare, has formed a working group to explore AI use in prior authorization. The group, comprising health plan and system executives along with patient advocates, aims to develop consensus on best practices. Brian Anderson, CHAI's CEO, expects the process to take about six months. The initiative seeks to address concerns about transparency in prior authorization processes. This effort aligns with CHAI's broader mission, which includes creating a national network of independent assurance labs for healthcare AI. Previously, CHAI released a draft Responsible AI Framework with guidelines for AI product evaluation.(Link)

11. FusionCare.AI Launches Revolutionary "Obesity Care in a Box" Platform at Future and Health Executive Summit

FusionCare.AI, a startup focused on transforming obesity and metabolic care, debuted at the 4th Annual "Future and Health Executive Summit" held at Verizon Innovation Lab. The company introduced an AI-enabled digital platform offering comprehensive obesity care services, including tailored treatment pathways and access to health professionals. Co-founder Dr. Pankaj Rajvanshi emphasized the platform's ability to support metabolic service lines and Obesity Centers of Excellence. The summit featured discussions with industry leaders from Mayo Clinic, Oracle, and Kaiser Permanente, highlighting innovation and technology as key drivers in healthcare's future. FusionCare.AI aims to address the obesity epidemic with precision and scalability. (Link)

12. Johnson & Johnson (NYSE: JNJ) Acquires Intra-Cellular Therapies for $14.6 Billion, Boosting CNS Portfolio

Johnson & Johnson has announced a $14.6 billion acquisition of Intra-Cellular Therapies, paying $132 per share, a 39% premium over Friday's closing price. The deal strengthens J&J's neuroscience portfolio, particularly with Intra-Cellular's schizophrenia and bipolar treatment, Caplyta. The acquisition follows Intra-Cellular's recent patent settlement, extending Caplyta's market exclusivity to 2040. Intra-Cellular's revenue grew 45% year-over-year in the first three quarters of 2024, reaching $481 million. This marks J&J's largest acquisition since buying Actelion for $30 billion in 2017 and represents the biggest biotech deal since Pfizer's $43 billion Seagen acquisition in March 2022. (Link)

13. Eli Lilly (NYSE: LLY) Acquires Scorpion Therapeutics' PI3Kα Pipeline for $2.5 Billion, Boosting Breast Cancer Drug Development

Eli Lilly has announced a $2.5 billion deal to acquire Scorpion Therapeutics' PI3Kα pipeline, including the clinical-phase candidate STX-478, at the J.P. Morgan Healthcare Conference. This move aims to challenge Novartis and Roche in the breast cancer market. The deal involves Lilly buying Scorpion but spinning out its non-PI3Kα assets into a new company. STX-478 showed

promising phase 1 results with a 23% response rate in breast cancer patients and potentially fewer side effects compared to existing treatments. This acquisition accelerates Lilly's efforts in developing next-generation PI3Kα inhibitors, following the company's decision to axe its previous candidate, LOXO-783, last year. (Link)

14. Gilead Sciences (NAS: GILD) and LEO Pharma Ink $1.7 Billion Deal to Develop Oral STAT6 Inhibitors for Inflammatory Diseases

Gilead Sciences has entered a major $1.7 billion deal with Leo Pharma, focusing on preclinical STAT6 research programs for inflammatory diseases. The partnership marks Gilead's deeper venture into inflammation, moving beyond its infectious disease roots. Gilead will pay $250 million upfront and lead oral program development, while Leo will focus on topical formulations. The deal targets diseases like eczema, asthma, and COPD, potentially competing with blockbuster drugs from AbbVie, Sanofi, and Regeneron. This collaboration aligns with Gilead's strategy to expand its inflammation portfolio and develop next-generation therapies for chronic inflammatory conditions, as stated by Flavius Martin, Gilead's executive VP of research. (Link)

15. GSK (LON: GSK) Acquires IDRx for $1.15bn, Bolstering Oncology Portfolio with Promising GIST Treatment

GSK has announced a $1.15bn acquisition of IDRx, a US biotech company specializing in gastrointestinal cancer treatments. The deal, revealed at the 2025 JP Morgan Healthcare Conference, includes a $1bn upfront payment and $150m in regulatory milestones. GSK gains full ownership of IDRx and its lead drug candidate, IDRX-42, a selective tyrosine kinase inhibitor targeting all major KIT mutations in gastrointestinal stromal tumors (GIST). IDRX-42, currently in Phase I/IIb trials, has shown promising results with a 29% overall response rate across all KIT mutation subsets. This acquisition aligns with GSK's strategy to strengthen its oncology portfolio and address unmet medical needs in gastrointestinal cancers. (Link)

16. AbbVie (NYSE: ABBV) and Simcere Zaiming Strike $1 Billion+ Deal for Multiple Myeloma Drug Candidate

AbbVie and Simcere Zaiming have entered into a license agreement for SIM0500, a promising drug candidate for relapsed or refractory multiple myeloma. The treatment, developed using Simcere Zaiming's proprietary T-cell engager platform, is currently in Phase I clinical trials in the US and China. Under the agreement, Simcere Zaiming will receive an upfront payment and could potentially earn up to $1.055 billion in option fees and milestone payments. This collaboration aims to advance the clinical development of SIM0500, with both companies expressing excitement about the partnership and the potential impact on multiple myeloma treatment. (Link)

17. Rappta Therapeutics and SpringWorks Therapeutics Forge $13 Million Deal for Novel Cancer Drug RPT04402

Rappta Therapeutics has entered into an exclusive global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue targeting Protein Phosphatase 2A (PP2A) complexes. The deal includes a $13 million upfront payment to Rappta, with potential for additional milestone payments and royalties. RPT04402 shows promise in treating PP2A mutant uterine cancer, demonstrating significant tumor regression in pre-clinical models. SpringWorks will oversee global development and commercialization, aiming to file an IND by the end of 2025. This partnership marks a significant step in developing a new class of anti-cancer drugs targeting the previously "undruggable" PP2A. (Link)

18. Synthego and AstraZeneca (LON: AZN) Forge Landmark CRISPR Licensing Deal, Revolutionizing Gene Therapy Development

Synthego, a leading CRISPR solutions provider, has secured a global licensing agreement with AstraZeneca for their novel CRISPR enzyme, eSpOT-ON (engineered ePsCas9). This strategic partnership grants Synthego exclusive rights to manufacture, distribute, and sublicense the cutting-edge nuclease for research and therapeutic applications. The collaboration aims to accelerate the development of transformative gene therapies by combining Synthego's expertise with AstraZeneca's innovative technology. Synthego CEO Craig Christianson emphasized the agreement's potential to streamline the path from concept to clinic, offering researchers access to advanced CRISPR tools at significantly lower costs. This partnership marks a pivotal moment in CRISPR therapeutics, promising improved health outcomes worldwide.(Link)

19. Helix and Komodo Health Partner to Enhance Clinico-Genomic Research

Helix, a population genomics leader, and Komodo Health, a healthcare technology company, have joined forces to enrich Helix's clinico-genomic datasets within the Helix Research Network (HRN). This partnership will incorporate insights from Komodo's Healthcare Map, providing a comprehensive view of patient-level data. The collaboration aims to support drug development research by offering deeper insights into medication usage, treatment adherence, and healthcare costs across various conditions. HRN, already the largest hereditary clinico-genomic database in North America, is expanding rapidly with a goal of over 1.5 million participants. This partnership is set to accelerate precision medicine research and therapeutic development. (Link)

20. Talkspace (NAS: TALK) Launches AI-Powered 'Insights' Feature to Enhance Therapeutic Care and Provider Efficiency

Talkspace, the leading online therapy platform, has introduced 'Insights,' an AI-powered feature designed to streamline therapist preparation and improve client care. The new tool synthesizes client data, including symptom assessments and session details, to generate pre-session primers and post-session updates for providers. Developed in collaboration with Talkspace clinicians, Insights aims to save preparation time and enrich the therapeutic process. The feature builds on the platform's existing 'smart notes' capability and adheres to HIPAA regulations, ensuring patient confidentiality. Talkspace's CEO, Dr. Jon Cohen, emphasizes that this innovation reinforces the company's position as a leader in behavioral health technology. (Link)

21. Samsung Biologics to Boost Manufacturing Capacity with New Plant 5 Opening in April 2025 and Considering 6th Plant

Samsung Biologics announced key business updates at the 43rd J.P. Morgan Healthcare Conference. The company will open Bio Campus II in 2025, with Plant 5 becoming operational in April, increasing total production capacity to 784,000 liters. Samsung Biologics is also considering a sixth plant, potentially raising capacity to 964,000 liters. The company has launched ADC services at a new dedicated facility and plans to open a Tokyo office this year. Additionally, Samsung Biologics is investing in pre-filled syringe capabilities, expanding development services, and enhancing digital systems to improve efficiency and client satisfaction. (Link)

22. Massive Bio Joins White House Cancer Moonshot Initiative, Unveils $15M Investment in AI-Driven Clinical Trial Platform

Massive Bio has been included in the White House Office of Science & Technology Policy's Cancer Moonshot Fact Sheet, highlighting its efforts to revolutionize clinical trial access. The company will debut at the 2025 JPMorgan Healthcare Conference, announcing a $15 million investment in its

AI-driven clinical trial matching platform. Massive Bio aims to serve 50,000 unique cancer patients annually, scaling to 250,000 globally by 2027. The platform features pre-screening hubs, real-time data analytics, and a patient-centric 'hub and spoke' model. This initiative focuses on improving access for underserved populations and accelerating just-in-time, decentralized trials worldwide. (Link)

23. Takeda Unveils Ambitious Pipeline Strategy at J.P. Morgan Healthcare Conference, Focusing on Six Potential Blockbusters

Takeda's CEO Christophe Weber outlined the company's future plans at the J.P. Morgan Healthcare Conference, highlighting six pipeline assets with potential blockbuster sales. These candidates, including oveporexton for narcolepsy, zasocitinib for psoriasis, and rusfertide for polycythemia vera, could collectively generate peak sales between $10-20 billion. The strategy aims to offset expected biosimilar competition to Entyvio in 2031. Weber emphasized the innovative nature of these drugs and their potential to change treatment paradigms. Takeda also remains open to in-licensing opportunities to bolster its pipeline, anticipating a period of limited generic exposure until 2031. (Link)

Healthcare Capital Markets & Innovation Summit

Providers | Payors | Life Science | Private Equity & Venture

May 28-29th 2025

Presented by

LAWRENCE, EVANS & CO., LLC
Investment Banking | Healthcare Finance | Consulting

Healthcare Dealmaking in "The Smart Health City"

The 5th annual Healthcare Capital Markets & Innovation Summit HCMIS May 28-29th 2025

Registration is now open – Early Bird only $495

Visit - www.healthcarecapitalmarkets.com

Healthcare Capital Markets & Innovation Summit (HCMIS) 2025 is based in Columbus OH "The Smart Healthcare City" This conference is where leading healthcare industry executives gather and speak on the latest investment and partnership topics.

In addition to hearing from top healthcare innovators, attendees will also have access to:

- Dealmaking & networking with industry leaders, executives, PE, VC, family offices, bankers, accountants, lawyers, and other professionals
- In-person one-on-one meetings with fellow event participants that can be locked in with a dedicated meeting scheduler
- Company presentations from executives seeking capital, partnerships, or to sell.
- ACG Columbus in collaboration with a breakfast event
- Healthcare Venture Studios (top leaders and investors in the space)

Proposed Panels and Speaker Topics

- Private Equity Investment and 2025 Outlook
- New Administration Healthcare Policy
- Growing Interest in Medspas, Injectables and Obesity Drugs
- Value Based Strategy and Update
- Health IT - Digital Health, RCM and Artificial Intelligence
- Behavioral Health
- Women's Health
- Rural and Access for Healthy Communities
- Cybersecurity Threats, Insurance Coverage and Due Diligence
- IPOs back in vogue?
- Bioastronautics (Space Health)
- Healthcare Venture Studio Models and Trends

In addition to seeking the most knowledgeable panelists, we give preference to conference sponsors. If your organization is interested in sponsoring, please contact us for a media package. For questions, contact us at the email info@healthcarecapitalmarkets.com or call 614-448-1304